Heron TherapeuticsNASDAQ: HRTX

-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 SAN DIEGO , July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.

SAN DIEGO, May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement ("PAS") submission to the U.S. Food and Drug Administration ("FDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN"). Heron expects to receive the assigned action date for completion of the FDA's review of this PAS within the next several weeks and anticipates an action date on this PAS to be between four (4) and six (6) months.

Does Heron Therapeutics (HRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Heron Therapeutics has made progress in shoring up its balance sheet and cutting expenses, improving its financial position. Revenue growth remains a challenge. The expanded label for Zynrelef and the partnership with CrossLink could help accelerate growth in 2024.

Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.